Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a class action lawsuit due to allegations of misleading investors regarding its prostate cancer therapeutic candidates and supply chain quality [1][2]. Group 1: Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025 [1]. - The lawsuit was filed on behalf of investors who purchased or acquired Telix securities during the class period [1]. Group 3: Allegations - The complaint alleges that during the class period, defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates, TLX591 and TLX592, as well as the quality of its supply chain and partners [2]. - Investors were reportedly surprised on July 22, 2025, when Telix disclosed an SEC investigation into its disclosures regarding the development of its prostate cancer therapeutic candidates [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA, citing deficiencies in chemistry, manufacturing, and controls, and requested additional data for the drug product used in the phase 3 clinical trial [3]. Group 4: Impact on Stock - Following the announcement of the SEC investigation and the CRL from the FDA, the price of Telix's American Depositary Shares (ADSs) declined [3].